Physician profile
Jason Bailey
NPI 1265694541
$60,431.74
in general payments reported to CMS, 2019-2025
8 companies · $16K in 2025
The $16K reported for 2025 was more than what 95% of Infectious Disease providers received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,117 · 2020: $2,859 · 2021: $2,096 · 2022: $5,494 · 2023: $11K · 2024: $18K · 2025: $16K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $32K · Travel and Lodging: $9,994 · Consulting Fee: $1,820 · Food and Beverage: $1,522.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $31,529.00 |
| Travel and Lodging | $9,994.47 |
| Consulting Fee | $1,820.00 |
| Food and Beverage | $1,522.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $59,769.31 | 2019-2025 | Biktarvy |
| Crossroads Extremity Systems, LLC | $436.09 | 2021 | |
| Merck Sharp & Dohme LLC | $112.30 | 2019-2020 | |
| Vapotherm INC | $31.18 | 2019 | |
| Tetraphase Pharmaceuticals, INC. | $28.83 | 2019 | |
| Abbott Laboratories | $22.60 | 2022 | |
| Ferring Pharmaceuticals INC. | $16.01 | 2024 | Rebyota |
| Insmed, INC. | $15.42 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jason Bailey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.